Raiffeisen Corporate Finance advised Kinarus AG as project coordinator, listing and settlement agent. Kinarus is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therpeutics for the treatment of viral, respiratory, and ophthalmic diseases, in the reverse takeover of the SIX Swiss Exchange-listed Perfect Holding AG. The combined entity will be renamed Kinarus Therapeutics Holding on June 9, 2022 and trade on SIX Swiss Exchange under “KNRS”.
Raiffeisen Switzerland
Advised in the sale of
Perfect Holding AG
to